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Introduction: High-dose methotrexate (MTX) is used in the
treatment of proliferative diseases such as acute lymphoblastic
leukemia. Therapeutic drug monitoring of plasma MTX is important
to monitor efficacy and adverse events. The authors aimed to develop
a liquid chromatography, electrospray ionization, tandem mass
spectrometry (LC-ESI-MS/MS)-based method to determine MTX in
plasma for therapeutic drug monitoring and pharmacokinetic studies.
Methods: Samples were analyzed using a Waters Acquity UPLC
and Quattro Premier XE. A Waters Acquity UPLC BEH C18 column
(2.1 mm · 100 mm, 1.7 mm) was used running an isocratic mobile
phase of 21% methanol and 10 mM ammonium bicarbonate. The
electrospray was operated in the positive ionization mode monitoring
the following mass transitions: m/z 455.2 . 308.2 for MTX and m/z
458.2 . 311.2 for MTXd3. The analysis combined straightforward
sample preparation, consisting of dilution and protein precipitation,
with a 3-minute run time.
Results: The method was linear up to 50 mM (r2 . 0.99), and the
coefficient of variation was ,6% for intraday and ,10% for inter-
day precision. Average recovery was 99%. There were no significant
matrix effects. The lower limit of quantitation, defined as the lowest
concentration at which the coefficient of variation ,20% and S/N .
1:10, was 5 nM. Method comparison with the Abbott TDx fluores-
cent polarization immunoassay (FPIA) showed excellent agreement,
and a small but significant negative constant bias was detected (LC-
MS/MS = 0.98 · FPIA 2 7.3).
Conlusions: The authors developed a specific and sensitive stable
isotope dilution LC–ESI–MS/MS method to monitor MTX concen-
trations in plasma within the clinically relevant range. The method
can be easily applied in clinical laboratories because it combines
straightforward sample pretreatment with LC-MS/MS.
Key Words: methotrexate, human plasma, mass spectrometry, sta-
ble isotope, FPIA, therapeutic drug monitoring
(Ther Drug Monit 2012;34:432–439)
INTRODUCTION
Methotrexate (MTX) is a folate antagonist that has been
used in clinical practice for 5 decades. It is used in the
treatment of acute lymphoblastic leukemia (ALL),1,2 which is
the most frequent cancer in children aged less than 15 years,3
and other proliferative diseases.4 Treatment is often limited
due to severe toxicity,5 and monitoring of plasma MTX is
important to assess efficacy and adverse events.3,6,7
Plasma MTX is commonly measured using immuno-
assays such as the fluorescent polarization immunoassay (FPIA)
and enzyme-multiplied immunoassay technique8 from Abbott
and Siemens, respectively. Immunoassays need limited sample
preparation, and relatively fast turnaround times can be achieved,
which make them suitable for routine clinical application.
However, immunoassays are expensive and are hampered
by interference such as cross-reaction with folates and MTX
metabolites, leading to low specificity.9–12 Although immuno-
assays are easy to implement and run, the large plasma concen-
tration range of MTX in high-dose (HD) MTX treated patients
(20 nM to 100 mM) imposes the need for testing samples in
serial dilution.12,13 This compromises the assay’s throughput
unless an extensive infrastructure is present. Furthermore,
immunoassays generally display poor sensitivity9; the lower
limit of quantitation (LLOQ) of most immunoassays for MTX
lies in the 20-nM range. Although this is below the clinically
relevant concentration [therapeutic drug monitoring (TDM) of
MTX plasma concentrations generally stops ,100 nM], phar-
macokinetic studies might benefit from a lower LLOQ.
Several high-performance liquid chromatography
(HPLC)–based methods have been developed to improve spec-
ificity and sensitivity of plasma MTX detection. Commonly
used detection methods include fluorescence detection,6,14–16
UV detection,17 and mass spectrometry.18–21 Although HPLC-
based methods have many advantages, most HPLC methods
rely on UV detection or fluorescence, which makes these
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methods subject to interference by other compounds, most no-
toriously folates and the deconjugated MTX form 4-amino-4-
deoxy-N-methylpteroic acid (DAMPA),22 leading to poor spec-
ificity and lower sensitivity (high LLOQ).
Liquid chromatography–tandem mass spectrometry
(LC–MS/MS) is becoming a more routine method in the clin-
ical laboratory.23 LC–MS/MS is generally more specific than
either conventional HPLC or immunoassay methods. In
addition, these LC–MS/MS–based methods will in most cases
result in shorter analysis times than do other HPLC methods,
leading to higher throughput.24 Therefore, we aimed to
develop and validate a new LC–MS/MS method for the mea-
surement of MTX in plasma.
METHODS
Chemicals and Blood Specimens
MTX was purchased from Schircks Laboratories (Jona,
Switzerland). Deuterium-labeled MTX (MTXd3) was used as
internal standard (IS) and was purchased from Toronto
Research Chemicals Inc (North York, Canada). Chemical
structures of MTX and the deuterated analog are illustrated in
Figure 1. LC–MS grade methanol and water were obtained
from Biosolve (Valkenswaard, The Netherlands). Ammonium
bicarbonate and perchloric acid (70% vol/vol) were purchased
from Sigma (Zwijndrecht, The Netherlands). Ammonia
(25% vol/vol) was purchased from Merck (Schiphol-Rijk,
The Netherlands).
Blinded drug-free and patient blood samples were
used for development and validation of the method. Blinded
samples were left over from routine analysis at the
department of Clinical Chemistry and the Hospital Phar-
macy; hence, no medical–ethical approval was necessary
for this study.
Instruments
Analyses were performed on an LC–MS/MS system
consisting of a Waters Acquity UPLC (Waters Corporation,
Etten-Leur, The Netherlands) equipped with a 20-mL sample
loop and a Quattro Premier XE (Waters Corporation, Etten-
Leur, The Netherlands) triple quadrupole mass spectrometer
with an electrospray ionization source operated in the positive
ionization mode.
Chromatographic Conditions
Chromatography was performed using partial loop
injection of 10-mL sample on a Waters Acquity UPLC
BEH C18 column (2.1 mm · 100 mm, 1.7 mm) maintained
at 358C. The mobile phase consisted of 10 mM ammonium
bicarbonate adjusted to pH 10 with 25% ammonia as the
aqueous component (A), and methanol as the organic com-
ponent (B). The system was maintained at a flow rate of
0.3 mL/min. keeping an isocratic concentration of 21% B.
After every 80 samples, the column was flushed or 10 minutes
with 100% methanol at a flow rate of 0.3 mL/min followed by
reequilibration with 21% B at a flow rate of 0.3 mL/min.
FIGURE 1. Chromatograms and chemical structures of MTX and IS (MTXd3). The location of the deuterium-enriched methyl-
group is highlighted. The SRM for both MTX and MTXd3 are depicted in the table.
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Mass-Spectrometery Detection
The electrospray ionization source was operated in the
positive mode with the following selected reaction monitoring
(SRM) mass transitions: m/z 455.2 . 308.2 for MTX and
458.2 . 311.2 for MTXd3 (Fig. 1).
Other mass-spectrometer settings were as follows:
capillary voltage 1.00 kV, cone voltage 30 V, collision energy
20 eV, source temperature 1208C, desolvation temperature
3508C at a gas flow of 700 L/h, and cone gas flow 50 L/h.
Argon was used as collision gas at a flow rate of 0.20 mL/min.
Preparation of Standards
Stock solutions were prepared in 0.1 M ammonia at
concentrations of 1836.6 mM for MTX and 10 mM for
MTXd3. Both stock solutions were stored at 2808C. The
stock solution of MTXd3 was diluted with LC–MS grade
water to a working solution of 100 nM to serve as the IS.
The working solution was prepared freshly for each batch of
prepared samples.
Preparation of Calibrators and Quality
Control Samples
Frozen drug-free plasma was thawed at room temper-
ature while rotating and then spiked with MTX to a final
concentration of 50 mM. A 16-point calibration range was
obtained by 1:1 serial dilution, containing 3.05; 6.10; 12.21;
24.41; 48.83; 97.66; 195.31; 391.63; 781.25; 1562.5; 3125;
6250; 12,500; 25,000; and 50,000 nM MTX and a blank
sample (0 nM). A fresh calibration curve was prepared for
each run.
Quality control (QC) samples were prepared in drug-
free plasma at 5 different concentrations: 10; 50; 500; 5000;
and 50,000 nM MTX. Aliquots were stored at 2808C and
thawed at 48C while rotating.
Sample Preparation
Plasma was obtained by centrifuging K2–ethylenedia-
minetetraacetic acid (EDTA) whole-blood tubes at 2700g. A
50-mL plasma aliquot was added to 450-mL drug-free plasma
and then supplemented with 500 mL cold IS solution (100 nM
MTXd3 in H2O). Protein precipitation was done by the addi-
tion of 800 mL of cold 16% perchloric acid to the diluted
sample while vortexing. The samples were placed on ice for
30 minutes to enhance precipitation, after which they were
centrifuged for 10 minutes at 2700g. The clear supernatant
was transferred to a sample vial and placed in the autosampler
of the LC–MS/MS system maintained at 48C. The injection
volume was 10 mL.
Calibrators and QC samples were also prepared as
described above. Concentrations were multiplied by 10 to
correct for dilution.
Validation Procedures
Method validation was adapted from the 2001 Food and
Drug Administration guidelines25 and Matuszewski et al.26 It
consisted of selectivity, IS integrity, carryover, stability
(short/long-term storage, freeze/thaw), recovery, matrix
effects, linearity, LLOQ, precision (interday/intraday), and
accuracy in comparison to FPIA (gold standard). All samples
were measured in duplicate unless otherwise specified.
Selectivity of the detection was determined by measur-
ing 20 different drug-free samples, which were prepared as
described in the “Materials and Methods” section but replac-
ing MTX and IS solution with LC–MS grade water. The
average background signal was calculated for both MTX
and MTXd3 and was used as noise when calculating the
signal/noise ratio.
IS integrity was tested by measuring the presence of
MTX, MTX mass+1, MTX mass+2, and MTX mass+3 in
LC–MS/MS grade water spiked with 100 nM IS.
Carryover was assessed by triplicate measurement of
a spiked plasma sample with high concentration (50 mM)
directly followed by triplicate measurement of a sample with
low (50 nM) concentration and calculated as [(Low1 – Low3)/
(High3 2 Low3)] · 100%.27 This was repeated in 3 different
plasma batches.
Stability of MTX in plasma was studied by measuring
the stored QC samples after 1 week, 6 weeks, and 6 months
at 2808C. The stability of MTX after sample preparation was
studied by storing a prepared concentration range (3–50,000
nM) in the autosampler at 48C for 16 days. Freeze/thaw
stability was investigated by measuring QC samples after
3 successive cycles of freezing at 2808C and unassisted
thawing on ice. All the samples were measured 5 times from
the same vial, and the results from these stability experiments
were compared with those of freshly prepared and directly
measured samples.
Recovery of the sample preparation was determined by
spiking 10 different blank plasma samples with 3 different
MTX concentrations (50, 500, 5000 nM) and IS (100 nM)
before and after sample preparation. The recovery was calcu-
lated with the following formula: Recovery (%) = (MTX spiked
before sample prep/MTX spiked after sample prep) · 100%.
Matrix effects can have a detrimental effect on MS-
based analysis,28 and both absolute and relative matrix effects
can occur.26Absolute matrix effect was defined as the differ-
ence in response between analyte spiked in sample matrix
versus analyte spiked in pure solvent. A relative matrix effect
is described as the variation in response between different
samples in a similar matrix and can be expressed as the
coefficient of variation (CV) between the slopes of reference
curves made in different samples of the same matrix. The
evaluation of matrix effects was performed according to the
recommendations of Matuszewski et al.26 Ten reference
curves were prepared by spiking 10 different drug-free
plasma batches with 5 concentrations (10 nM, 50 nM,
500 nM, 5 mM, and 50 mM) of MTX after sample prepara-
tion. The slopes of these reference curves in the different
drug-free plasma batches were compared with the slope of
a reference curve prepared in purified water to determine the
absolute matrix effect. The absolute matrix effect was defined
as: Absolute matrix effect = (mean slope plasma sample/slope
distilled water) · 100%. By comparing the reference curves
of the 10 standard lines from the 10 different plasma samples
the relative matrix effect was calculated, which was expressed
as: Relative matrix effect = 100% 2 CV% of the slopes of
the 10 reference curves. Furthermore, the maximum slope
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difference was calculated as the difference in percentage
between the lowest slope and highest slope of the 10 refer-
ence curves. All matrix effects were calculated with and with-
out correction by the IS. Slopes were calculated by linear
regression analysis.
Linearity of the method was determined by spiking drug-
free plasma with 22 different concentrations of MTX in a range
of 3–250 mM. This range reflects the full clinical range of
MTX concentrations reported the past year at the Hospital
Pharmacy of the Erasmus MC. The samples were measured
5 times from the same vial, and the experiment was repeated in
a second drug-free plasma batch. Linearity was considered
acceptable if the coefficient of determination (R2) was .0.99
for each calibration curve and if the lack of fit was ,3.75.
LLOQ was determined by spiking drug-free plasma
samples with different levels of MTX covering a range of
3–50,000 nM. These were measured 10 times from the same
vial for each concentration level and the experiment was
repeated in a second drug-free plasma batch. The LLOQ
was defined as the lowest concentration of a serial dilution
with a CV%,20%, while having an area of at least 10 times
the average area of the drug-free plasma samples used for the
selectivity experiment and 5 times the area of the blank
sample (0 nM).
Precision and accuracy were determined by measuring
QC samples 5 times on 20 consecutive working days for
interday precision. The QC samples were thawed and pre-
pared as described in the “Materials and Methods” section.
Everyday, a new batch of drug-free plasma was used for the
dilution of the QC samples. The intraday precision was
assessed by measuring QC samples 20 times in 1 run. This
was repeated on a different day with another drug-free plasma
batch for the dilution of the QC samples. Precision was
expressed as CV% and accuracy as bias (%error).
Method Comparison
Blood samples from ALL patients were collected in
K2–EDTA tubes from November 2009 to March 2011 by the
Hospital Pharmacy of the Erasmus MC. These were used for
routine measurement of plasma MTX using the FPIA on an
Abbott TDx FLx Immunology Analyzer (Abbott Diagnostics,
Hoofddorp, The Netherlands).
In total, 194 plasma samples from 34 ALL patients
receiving 2–5 g/m2 MTX for 24 hours were measured using
both FPIA and LC–MS/MS. After measurement by the Hos-
pital Pharmacy, surplus plasma was kept at 2208C before
measurement by LC–MS/MS. All the samples were measured
twice from the same vial on the LC–MS/MS to be able to
detect carryover.
The samples were measured in random order to reduce
sample selection bias. Samples were remeasured by LC–MS/
MS when (1) duplicate measurement differed .15%, (2)
samples were below the LLOQ, or (3) above the upper limit
of quantitation. All the samples that were remeasured were
both obtained from the original prepared sample and from
freshly prepared sample. Samples that were below the LLOQ
were repeated undiluted, whereas samples that were above the
upper limit of quantitation were diluted 1:100 in drug-free
plasma before preparation.
Statistics
Quantitation was performed using peak area ratio of
analyte to IS. Microsoft Excel and Analyse-it for Microsoft
Excel (version 2.20) were used to perform linear regression
(matrix effects studies, calibration lines, linearity). Validation
studies were performed according to CLSI EP-6 and Passing
and Bablok regression analysis with 95% confidence intervals
(method comparison). Precision was expressed as coefficients
of variation (CVs): CV% = (SD/mean) · 100%. MassLynx
software (Waters) was used for the analysis of chromato-
grams. The processing of MS data was done using QuanLynx
software (Waters).
RESULTS
Method Performance
To establish the appropriate MS conditions, a standard
solution was infused directly into the MS for optimization.
Collision-induced dissociation of the protonated molecules
was performed, and the product ions with the highest
abundance were selected for SRM analysis. Mass transitions
obtained in positive mode were 455.2 . 308.2 for MTX and
458.2 . 311.2 for MTXd3 (Fig. 1). Other mass transitions
were detected but their S/N ratio was too low to be used for
quantitation.
When measuring 20 drug-free samples, the signal did
not rise above the noise, showing good selectivity of the assay
and that no interferences were detected. 100 nM MTXd3 in
water yielded 0%, 0%, 3%, and 97% for MTX, MTX mass +
1, MTX mass + 2, and MTX mass + 3, respectively, showing
good integrity and purity. Mean carryover was 0.021%.
The results for the stability experiments are presented in
Table 1. Untreated plasma samples were stable when stored
for 1 week at 2808C (mean recovery: 106%), 6 weeks
at 2808C (mean recovery: 106%), or 6 months at 2808C
(mean recovery: 107%). After preparation, the samples were
stable when kept in the autosampler at 48C for up to 16 days
(mean recovery: 102%). Furthermore, this was confirmed in
11 patient samples that were remeasured after 1 week at 48C
(mean recovery: 110%). Three subsequent freeze–thaw cycles
did not significantly influence MTX concentration. The
observed decrease in response after freeze–thaw was 3%.
Average recovery ranged from 96% to 102% for all
concentrations (50, 500, 5000 nM) of MTX with a CV% of
,15% for each concentration when based on the area of the
MTX peaks. After correction with the IS, average recovery
ranged from 98% to 101% for all concentrations with a CV%
of ,6% for each concentration (Table 2).
TABLE 1. Recovery of MTX in Plasma
Sample Concentration
(nM) (n = 10)
Measured
Concentration
(nM ± SD)
Average
Recovery
(% ± SD) CV%
50 50.4 ± 2.5 101 ± 5 5
500 503.2 ± 14.6 99 ± 5 5
5000 5001.6 ± 175.7 98 ± 6 6
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The absolute matrix effect calculated without correction
for the IS was 71% with a relative matrix effect of 81% and
a maximum slope difference of 67%, showing large variation
between the different samples. After correction with the IS,
the absolute matrix effect improved to 94% with a relative
matrix effect of 98% and a maximum slope difference of 7%.
All slopes showed an r2 . 0.999. Matrix effects tested in
samples without dilution in drug-free plasma during sample
preparation yielded similar results (Table 3).
The method was linear up to 50 mM (y = 20.326 +
0.997x) and subsequent validation samples and QC
samples were analyzed using calibration curves of 3 nM
to 50 mM (see Data, Supplemental Digital Content 1,
http://links.lww.com/TDM/A15). These were linear (r2 .
0.998, lack of fit ,0.85) throughout the validation.
When determining the LLOQ, the CV% did not
become .20% at any concentration other than the blank
(0 nM) sample (see Data, Supplemental Digital Content 2,
http://links.lww.com/TDM/A16). In all samples, the signal to
noise ratio was better than 10:1. The LLOQ was set at 5 nM
because at this concentration there was always (1) a visual and
distinguishable peak present in every calibration curve and (2)
a response 5 times higher than the response of the lowest
sample of the calibration curve (0 nM). The precision profile
of the method is shown in Table 4. Precision ranged between
2.1% and 6.5% for intraday variation and between 5.8% and
11.0% for interday variation for the total range of tested MTX
concentrations. The mean bias (%error) ranged from 211.3%
to 14.5% for intraday precision and 29.7% to 14.4% for the
total range of tested MTX concentrations.
Method Comparison
The 194 HD-MTX patient plasma samples were com-
pared between methods. Duplicate measurements on the LC–
MS/MS always showed a CV ,10% with the exception of 14
samples, of which 10 samples were below the LLOQ of either
the FPIA or the LC–MS/MS and were therefore excluded from
the comparison. The other 4 samples contained low concen-
trations of MTX (20–36 nM) and were preceded by high con-
centration samples (35,088–146,851 nM). The observed
difference between duplicates (6–45 nM) was similar to the
expected carryover (7–31 nM) assuming the 0.02% found pre-
viously, suggesting carryover as the cause. Another 9 samples
were excluded because MTX plasma concentrations were
below the LLOQ of the FPIA and therefore not reported as
numerical data but as “,20 nM” by FPIA. All the samples for
which the CV was .10% were remeasured both from the
original prepared sample and from freshly prepared samples
after which all samples had duplicates with a CV,10%.
The comparison of the remaining 175 samples showed
good agreement between methods: [LC–MS/MS = 0.98 (95%
CI: 0.95–1.02) · FPIA27.3 nM (95% CI:210.96 to25.34)]
(Fig. 2, insert). A slight, nonsignificant, proportional bias was
present, and a small but significant constant bias of 27.3 nM
was found for the complete sample set. Changing the method
comparison to the low (0–500 nM), high (500–50,000 nM),
or complete sample concentration range did not give a signif-
icant difference in slope or bias. For the lower concentration
range (0–500 nM), which contained 75% of all patient
samples, good agreement was obtained [LC–MS/MS = 1.00
(95% CI: 0.94–1.06) · FPIA 28.51 nM (95% CI: 211.06
to 25.88)] (Fig. 2).
DISCUSSION
We developed a straightforward and robust LC–MS/
MS–based method for the measurement of MTX in human
TABLE 2. Stability of Stored Spiked Plasma
Conditions
Average
Recovery (%)
(Range)
Before sample preparation* 1 wk 2808C 106 (95–115)
6 wks 2808C 106 (100–115)
6 mos 2808C 107 (103–114)
Freeze/thaw* (3 Cycles 2808C) 97 (92–99)
After sample preparation† 1 d 48C 102 (93–115)
1 wk 48C 102 (91–110)
2 wks 48C 102 (93–113)
*The average recovery represents the recovery of the different QC sample
concentrations, measured in 5-fold and compared with the results of the freshly
prepared QC samples.
†The average recovery represents the recovery of a prepared calibration curve,
measured in 2-fold and compared with the results of the freshly prepared calibration
curve.
TABLE 3. Matrix Effects of 10 Different Plasma Samples*
Sample Concentration
Average Matrix
Effect (%) CV%
Relative Matrix
Effect (%)
Maximum Slope
Difference†(%)
Diluted plasma‡ With IS 94 2 98 7
Without IS 71 19 81 67
Undiluted plasma With IS 96 2 98 6
Without IS 72 17 93 67
All slopes were r2 . 0.999 when corrected for IS.
*Matrix effect is expressed as percent recovery and calculated by comparing the slopes of reference curves made in 10 different plasma matrices with the slope of a reference curves
made in water.
†The maximum slope difference shows the percent difference between the largest and smallest slope, indicating the variance between slopes in different matrices.
‡1:10 in drug-free plasma
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EDTA plasma. Although other mass spectrometry–based meth-
ods have been reported for the detection of MTX in plasma,
most methods do not use stable isotope-labeled IS. Further-
more, these methods generally have higher LLOQs29–31 or
use more expensive and work-intensive sample preparation
and machinery.18,32 When compared with traditional methods
of MTX TDM (such as FPIA), our method has improved
LLOQ and has a large dynamic range.
The presented method does not require expensive and
time-consuming sample preparation, such as solid-phase
extraction, and because of the use of a stable isotope-labeled
IS, it is a very useful method for implementation within
a clinical laboratory. The short analysis time of 3 minutes
makes the method attractive for high-throughput settings and
clinical studies. Improvements in LLOQ can be made with the
addition of better sample cleanup, such as SPE, but this would
also drive up the cost and preparation time of the method.
Alternatively, LLOQ may be improved by reducing the
dilution factor. However, due to the dilution of patient sample
in drug-free plasma, less volume is needed making the
method suitable for use in very small sample volumes such
as in pediatric samples.
Although carryover is only 0.02%, the difference in
maximum plasma concentrations in HD-MTX treatment can
be as high as 100-fold. When measuring very low concen-
tration samples (,100 nM) after very high concentration
samples (.50 mM), this could lead to falsely increased
MTX concentrations in the low concentration range as was
seen when patient samples were measured in random order.
Samples with a low concentration of MTX measured directly
after samples with a high concentration of MTX had a dis-
crepancy between duplicates that fitted roughly with the
0.02% carryover that was determined. The use of duplicate
measurement is important to detect and counter this. For most
TDM purposes, this will not pose any problems as the clinical
cut-off for TDM is usually approximately 200 nM. However,
when dealing with samples in the setting of carboxylase–G2
treatment, carryover might present a problem due to the large
difference in MTX concentration between patient samples as
a result of MTX breakdown by the enzyme.12,13,33
TABLE 4. Intraday and Interday Precision
Expected Concentration (nM)
Measured Concentration Intraday
Precision (nM; n = 20)*
Measured Concentration Interday
Precision (nM; n = 20)†
Mean ± SD CV% Bias (%error) Mean ± SD CV% Bias (%error)
10 11.4 ± 0.76 6.5 14.5 11.6 ± 1.27 11.0 14.4
50 54.9 ± 1.95 3.5 9.7 53.5 ± 3.13 5.8 7.5
500 543.9 ± 17.84 3.3 8.8 536.3 ± 40.43 7.5 7.1
5000 4947.4 ± 168.85 3.4 21.1 5073.1 ± 465.15 9.2 1.3
50,000 44,335.1 ± 918.77 2.1 211.3 45,413.0 ± 3322.88 7.3 29.7
*The intraday precision summarizes 20 replicate measurements at each concentration of MTX during 1 day.
†The interday precision summarizes 20 different experiments from 20 consecutive days with measurement done in 5-fold each day.
FIGURE 2. Comparison of plasma MTX between the Abbott FPIA on the TDx analyzer (x-axis) compared with the LC–MS/MS
method (y-axis) (n = 175). Samples shown are in the range of 0–500 nM MTX, comprising 75% of all patient samples (n = 131).
Left panel: Passing and Bablok regression was used to compare both methods. The insert shows the comparison of the whole
concentration range (0–170 mM MTX). Right panel: Bland–Altman plot of differences between observed MTX concentrations by
FPIA and LC–MS/MS methods. Solid line represents bias (29.02 nM), and dotted lines represent 95% limits of agreement
(270.13 to 52.08).
Ther Drug Monit  Volume 34, Number 4, August 2012 An LC–MS/MS Method to Measure Methotrexate
 2012 Lippincott Williams & Wilkins 437
Recovery based on peak area was moderate with high
variance, but this was corrected for by the use of the stable
isotope-labeled IS, leading to more reproducible measure-
ments and a recovery of approximately 100%. The use of
a deuterium-labeled IS also compensated for matrix effects.
When using the peak areas to calculate matrix effects,
a prominent absolute matrix effect was detected, which was
almost completely corrected for by the use of the IS. The
relative matrix effect caused by using different plasma
batches is also corrected for by use of the IS. Both the
recovery and matrix effect experiments emphasize the need
for a proper IS when working with complex matrices such as
biological samples in an LC–MS/MS setting.
Matrix effects in undiluted samples were also very low
after correction for the IS, which indicates that the dilution
step in drug-free plasma is optional and leads to the
possibility of measuring very low sample concentrations
(,LLOQ) without dilution.
As shown by the method comparison, a good agree-
ment was found with the results of FPIA analysis. This
correlation was somewhat unexpected due to reports about
the poor specificity of the FPIA method.9,11,33 The few out-
liers that were found and the observed small constant bias
might be caused by several reasons. First, the FPIA might
measure higher concentrations because of its nonspecific
measurement of MTX metabolites such as DAMPA. Second,
differences might exist in the calibration between methods
(traceability chain). Third, calibration errors within the labo-
ratory might also have caused the constant bias between FPIA
and LC–MS/MS. Because there is neither a reference method
nor standard reference material for MTX in plasma, it is
difficult to speculate about the accuracy of the methods. How-
ever, in line with Food and Drug Administration guidelines,
our LC–MS/MS method showed a small positive bias (%error
,7.1 for interday and ,8.8 for intraday) in the clinically
relevant concentration range based on the spiked samples
and the intraday recovery (Table 4). In the higher concentra-
tion range, the bias was slightly negative (%error 29.7 for
interday and 211.3 for intraday). In certain situations, immu-
noassays such as the FPIA method may be hampered by
interference of MTX metabolites. For example, our method
was able to measure the rapid disappearance of plasma MTX
in patients treated with carboxylase–G2 for adverse events,
whereas the FPIA method was hampered by falsely high
MTX concentrations due to interference from the methotrex-
ate metabolite DAMPA (data not shown). This observation
was confirmed by the literature.12,13
In conclusion, we describe a LC–MS/MS–based
method to measure MTX in plasma with minimal sample
pretreatment, relative short analysis time, and good perfor-
mance that can be applied to routine clinical TDM.
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